ABZA Abzena

TIDMABZA

RNS Number : 0771X

Abzena PLC

21 November 2017

Abzena plc

Notice of half year results

Cambridge, UK, 21 November 2017 - Abzena plc (AIM: ABZA, 'Abzena' or the 'Group'), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, will publish its half year results for the six months to 30 September 2017 on Tuesday, 12 December 2017.

A presentation for analysts will be held at 09:30am on 12 December 2017 at the offices of Instinctif Partners, 65 Gresham Street, London EC2V 7NQ.

-Ends-

Enquiries:

 
   Abzena plc 
    John Burt, Chief Executive 
    Officer Julian Smith, Chief 
    Financial Officer                  +44 1223 903498 
   Numis (Nominated Adviser and 
    Broker) 
    Clare Terlouw / James Black        +44 20 7260 
    / Paul Gillam                       1000 
   N+1 Singer (Joint Broker)           +44 20 7496 
    Aubrey Powell / Liz Yong            3000 
   Instinctif Partners                 +44 20 7457 
    Melanie Toyne Sewell / Alex         2020 
    Shaw / Deborah Bell                 abzena@instinctif.com 
 

About Abzena

Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.

The term 'ABZENA Inside' is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on 'ABZENA Inside' products.

Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA):

-- Immunology research studies, including immunogenicity assessment of candidate biopharmaceutical products;

   --      Protein engineering to create humanized antibodies and deimmunised therapeutic proteins; 
   --      Cell line development for the manufacture of recombinant proteins and antibodies; 

-- Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies;

-- Contract synthetic chemistry and bioconjugation research services, focused on antibody-drug conjugates (ADCs);

-- Proprietary site-specific conjugation technologies and novel payloads for ADC development; and

   --      GMP manufacturer of ADC linkers, payloads & combined linker-payloads. 

For more information, please see www.abzena.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORMMMZMRMDGNZG

(END) Dow Jones Newswires

November 21, 2017 04:51 ET (09:51 GMT)

Abzena (LSE:ABZA)
Historical Stock Chart
From Mar 2024 to Apr 2024

Abzena (LSE:ABZA)
Historical Stock Chart
From Apr 2023 to Apr 2024